COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMPS COMPASS Pathways plc

Market Closed 01-16 16:00:00 EST

7.35

+0.04

+0.55%

盘后7.30

-0.05-0.68%

19:59 EST

High7.46	Low7.07	Vol748.73K
Open7.31	D1 Closing7.31	Amplitude5.35%
Mkt Cap705.73M	Tradable Cap429.34M	Total Shares96.02M
T/O5.51M	T/O Rate1.28%	Tradable Shares58.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMPS","market":"US","secType":"STK","nameCN":"COMPASS Pathways plc","latestPrice":7.35,"timestamp":1768597200000,"preClose":7.31,"halted":0,"volume":748726,"hourTrading":{"tag":"盘后","latestPrice":7.3001,"preClose":7.35,"latestTime":"19:59 EST","volume":9885,"amount":72557.658,"timestamp":1768611549318},"delay":0,"floatShares":58414107,"shares":96017044,"eps":-2.73668,"marketStatus":"Market Closed","change":0.04,"latestTime":"01-16 16:00:00 EST","open":7.31,"high":7.4608,"low":7.07,"amount":5506035.167072,"amplitude":0.053461,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.73668,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1600401600000,"exchange":"NASDAQ","adjPreClose":7.31,"preHourTrading":{"tag":"盘前","latestPrice":7.499,"preClose":7.31,"latestTime":"09:29 EST","volume":9297,"amount":69660.86561190001,"timestamp":1768573772508},"postHourTrading":{"tag":"盘后","latestPrice":7.3001,"preClose":7.35,"latestTime":"19:59 EST","volume":9885,"amount":72557.658,"timestamp":1768611549318},"volumeRatio":0.5125244804176837,"impliedVol":0.881,"impliedVolPercentile":0.1036},"requestUrl":"/m/hq/s/CMPS/wiki","defaultTab":"wiki","newsList":[{"id":"2601369620","title":"Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369620","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369620?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:18","pubTimestamp":1767874711,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on COMPASS Pathways, with a price target of $20.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-compass-pathways-cmps-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-compass-pathways-cmps-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPS"],"gpt_icon":0},{"id":"2601159369","title":"RBC Capital Sticks to Their Buy Rating for COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601159369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601159369?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:16","pubTimestamp":1767874607,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on COMPASS Pathways, with a price target of $16.00. The co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-compass-pathways-cmps-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-compass-pathways-cmps-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPS"],"gpt_icon":0},{"id":"2601366437","title":"Stifel Nicolaus Remains a Buy on COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366437?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:58","pubTimestamp":1767873516,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Paul Matteis from Stifel Nicolaus reiterated a Buy rating on COMPASS Pathways. The company’s shares closed yesterda...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-compass-pathways-cmps-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-compass-pathways-cmps-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","SF","CMPS","BK4139"],"gpt_icon":0},{"id":"2601870096","title":"Compass Pathways Says FDA Accepts Application for PTSD Treatment; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2601870096","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601870096?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:19","pubTimestamp":1767788347,"startTime":"0","endTime":"0","summary":"Compass Pathways  said Wednesday the US Food and Drug Administration accepted the investigational new drug application for COMP360 as a potential treatment of post-traumatic stress disorder, or PTSD.The move allows the company to proceed with a phase 2b/3 trial in patients with PTSD.Compass Pathways also said it amended its current term loan facility with Hercules Capital , increasing the facility to up to $150 million and helping the company maintain cash into 2027.Compass Pathways shares were up 5% in recent premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4135","BK4139","HTGC","CMPS"],"gpt_icon":0},{"id":"2601877876","title":"Compass Pathways Plc - on Jan 5, Co Entered Third Amendment to Loan and Security Agreement With Hercules","url":"https://stock-news.laohu8.com/highlight/detail?id=2601877876","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601877876?lang=en_us&edition=fundamental","pubTime":"2026-01-07 19:37","pubTimestamp":1767785863,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y717X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","BK4139"],"gpt_icon":0},{"id":"2601587787","title":"Compass Pathways Plc - Secures $150 Mln Loan Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601587787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601587787?lang=en_us&edition=fundamental","pubTime":"2026-01-07 19:37","pubTimestamp":1767785863,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y717X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2601872020","title":"Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2601872020","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601872020?lang=en_us&edition=fundamental","pubTime":"2026-01-07 19:33","pubTimestamp":1767785628,"startTime":"0","endTime":"0","summary":"Compass Pathways plc has released a new investor presentation highlighting recent progress in its clinical development programs for mental health indications, including treatment-resistant depression  and post-traumatic stress disorder . The company’s proprietary synthetic psilocybin formulation, COMP360, is currently being evaluated in the largest ongoing pivotal trial of a classic psychedelic, with Phase 3 COMP005 results demonstrating a statistically significant and clinically meaningful reduction in TRD symptom severity compared to placebo. The Data Safety Monitoring Board reported no unexpected safety findings for COMP360. Additional data from the ongoing COMP005 and COMP006 trials are expected in 2026. Compass Pathways reported a cash position of $186 million as of September 30, 2025, and anticipates its funding will support operations into 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using gener","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL9gvZ1j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2601872086","title":"Compass Pathways Expands Loan Facility With Hercules Capital to $150 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2601872086","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601872086?lang=en_us&edition=fundamental","pubTime":"2026-01-07 19:30","pubTimestamp":1767785442,"startTime":"0","endTime":"0","summary":"Compass Pathways plc has amended its existing term loan facility with Hercules Capital, Inc., increasing the total available financing to up to $150 million. As part of the amended agreement, Compass has drawn down $50 million, with the remaining funds accessible upon meeting certain conditions outlined in the loan agreement. The amendment also extends the interest-only period from January 2, 2026, to at least January 5, 2029, with potential for further extensions if specific milestones are achieved, and moves the loan’s maturity date from July 1, 2027, to January 5, 2031. This transaction is expected to provide greater financial flexibility, supporting Compass Pathways’ cash position into 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDLLXVlW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","HTGC","BK4135","BK4139"],"gpt_icon":0},{"id":"2601872775","title":"Compass Pathways Announces FDA Acceptance of Ind Application for Ptsd and Hosts Webinar on Ptsd and Trd","url":"https://stock-news.laohu8.com/highlight/detail?id=2601872775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601872775?lang=en_us&edition=fundamental","pubTime":"2026-01-07 19:30","pubTimestamp":1767785400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA7JR1SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2601778872","title":"Compass Pathways Plc - to Be Launch-Ready for Comp360 for Trd by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2601778872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601778872?lang=en_us&edition=fundamental","pubTime":"2026-01-07 19:30","pubTimestamp":1767785400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA7JR1SW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2601918998","title":"Compass Pathways Partners with Radial Health to Advance Psilocybin Treatment Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2601918998","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601918998?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:30","pubTimestamp":1767699015,"startTime":"0","endTime":"0","summary":"Compass Pathways plc has announced a strategic collaboration with Radial Health, Inc., a national network of interventional psychiatry practices in the United States. The partnership aims to innovate the patient experience and inform potential delivery models for COMP360, Compass’s investigational psilocybin treatment for mental health conditions, if approved by the FDA. This agreement with Radial marks Compass’s seventh collaboration, broadening its efforts to explore scalable care delivery models across various healthcare settings. The collaboration is expected to provide valuable insights into how COMP360 treatment could be integrated into mental health care in the U.S.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL80NS6L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"gpt_icon":0},{"id":"2601918548","title":"Compass Pathways Establishes Strategic Collaboration With Radial to Innovate Patient Experience and Inform Potential Delivery Model of Comp360","url":"https://stock-news.laohu8.com/highlight/detail?id=2601918548","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601918548?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:30","pubTimestamp":1767699000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA911SVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","BK4139"],"gpt_icon":0},{"id":"2601860882","title":"A small company can now advance its psychedelic into Phase 3. Here's why that matters to other psychedelic biotechs.","url":"https://stock-news.laohu8.com/highlight/detail?id=2601860882","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601860882?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:01","pubTimestamp":1767621660,"startTime":"0","endTime":"0","summary":"GH Research's stock rallied after saying the FDA lifted a hold on its experimental depression treatment. The FDA lifted its hold on GH Research's psychedelic drug, sending the company's shares soaring.A small biopharma company said its experimental depression drug is moving into Phase 3 trials, sending its shares soaring about 35% in premarket trading on Monday.GH Research  now plans to put GH001 into late-stage research sometime this year after the FDA lifted a clinical hold on the psychedelic, which it's testing in patients with treatment-resistant depression. Cantor Fitzgerald analysts expect the trial to kick off in the second half of the year.The Irish company is part of a growing class of drugmakers that aim to harness the power of psychedelic compounds against challenging-to-treat depressions like bipolar and postpartum.\"GHRS shares will benefit from what we expect will be growing investor enthusiasm around the psychedelics space this year, especially as other pivotal programs r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU0689626769.HKD","SG9999002224.SGD","LU2471134523.USD","LU0795875169.SGD","LU0882574055.USD","LU1496350502.SGD","LU1023059063.AUD","BK4588","IE00BLSP4452.SGD","LU1066051811.HKD","IE00B3T34201.USD","LU1074936037.SGD","LU2750360997.AUD","BK4581","LU0466842654.USD","IE00BFTCPJ56.SGD","LU1935042991.SGD","LU2430703251.USD","BK4534","IE00BSNM7G36.USD","IE0009355771.USD","CMPS","LU0289739699.SGD","LU0345770308.USD","LU0912757837.SGD","LU2112291526.USD","LU2430703095.HKD","LU1929549753.HKD","BK4139","LU2471134952.CNY","LU2133065610.SGD","LU1506573853.SGD","BK4539","LU2468319806.SGD","GHRS","LU0345770993.USD","IE00B19Z3581.USD","LU2505996681.GBP","LU2505996509.AUD","LU1894683348.USD","LU1244550577.SGD","LU1732799900.SGD","JNJ","LU1674673691.USD","IE00B2B36J28.USD","LU0234572021.USD","IE0002141913.USD","LU0124676726.USD","LU0432979614.USD"],"gpt_icon":0},{"id":"2590348982","title":"Compass Pathways Hosts Webinar on Commercial Preparations for TRD and PTSD Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590348982?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:30","pubTimestamp":1765279818,"startTime":"0","endTime":"0","summary":"Compass Pathways plc will host a webinar on January 7, 2026, from 10:00 to 11:30 am ET to discuss the company's commercial preparations for treatment-resistant depression  and clinical trial plans for post-traumatic stress disorder . The event will feature perspectives from key opinion leaders and industry experts on the current treatment landscape and unmet needs in TRD and PTSD. The company's management will also review commercial readiness for COMP360 in TRD and outline plans for a late-stage clinical program in PTSD. The webinar will be available via live audio webcast, with a replay accessible for 30 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL9971LL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2590348528","title":"Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (Trd) and Clinical Trial Plans for Post-Traumatic Stress Disorder (Ptsd) on January 7, 2026, 10:00Am Et","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590348528?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:30","pubTimestamp":1765279800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA5TTMKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2584135581","title":"Compass Pathways to Join Evercore and Piper Sandler Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2584135581","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584135581?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:30","pubTimestamp":1763638218,"startTime":"0","endTime":"0","summary":"Compass Pathways plc will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, FL, at 10:00am ET on December 2, 2025. The company will also join a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York, NY, at 1:30pm ET on December 3, 2025. Live audio webcasts of both events will be available on the Compass website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire  on November 20, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL6TV3Hg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK4139","PIPR","CMPS","EVR"],"gpt_icon":0},{"id":"2581708946","title":"Compass Pathways Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2581708946","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581708946?lang=en_us&edition=fundamental","pubTime":"2025-11-06 02:14","pubTimestamp":1762366440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 13:14 ET (18:14 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2581779191","title":"RBC Adjusts Price Target on COMPASS Pathways to $16 From $15, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779191","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581779191?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:55","pubTimestamp":1762354536,"startTime":"0","endTime":"0","summary":"COMPASS Pathways (CMPS) has an average rating of buy and mean price target of $17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMPS","BK4139"],"gpt_icon":0},{"id":"2581072681","title":"Compass Pathways to Participate in Stifel 2025 Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2581072681","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581072681?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:30","pubTimestamp":1762342234,"startTime":"0","endTime":"0","summary":"Compass Pathways plc will participate in the Stifel 2025 Healthcare Conference in New York on Tuesday, November 11, 2025. Management will present at 10:40 am ET, with a live audio webcast available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire  on November 05, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLH5VW6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"gpt_icon":0},{"id":"1153232989","title":"Stock Track | Compass Pathways Plunges 5.28% After Reporting Larger-Than-Expected Q3 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1153232989","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153232989?lang=en_us&edition=fundamental","pubTime":"2025-11-05 09:28","pubTimestamp":1762306135,"startTime":"0","endTime":"0","summary":"Shares of Compass Pathways PLC (CMPS) plummeted 5.28% in Tuesday's trading session following the release of its third-quarter financial results. The clinical-stage mental health care company reported...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CMPS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.compasspathways.com","stockEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.1855},{"period":"3month","weight":0.1273},{"period":"6month","weight":0.7093},{"period":"1year","weight":1.1554},{"period":"ytd","weight":0.0652}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.069796},{"month":2,"riseRate":0.2,"avgChangeRate":-0.087169},{"month":3,"riseRate":0.2,"avgChangeRate":-0.109959},{"month":4,"riseRate":0.4,"avgChangeRate":-0.016443},{"month":5,"riseRate":0.4,"avgChangeRate":-0.043784},{"month":6,"riseRate":0.6,"avgChangeRate":-0.018137},{"month":7,"riseRate":0.8,"avgChangeRate":0.262657},{"month":8,"riseRate":0.4,"avgChangeRate":-0.005792},{"month":9,"riseRate":0.2,"avgChangeRate":-0.10118},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.009194},{"month":11,"riseRate":0.333333,"avgChangeRate":0.034765},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.01163}],"exchange":"NASDAQ","name":"COMPASS Pathways plc","nameEN":"COMPASS Pathways plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest COMPASS Pathways plc(CMPS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"COMPASS Pathways plc,CMPS,COMPASS Pathways plc股票,COMPASS Pathways plc股票老虎,COMPASS Pathways plc股票老虎国际,COMPASS Pathways plc行情,COMPASS Pathways plc股票行情,COMPASS Pathways plc股价,COMPASS Pathways plc股市,COMPASS Pathways plc股票价格,COMPASS Pathways plc股票交易,COMPASS Pathways plc股票购买,COMPASS Pathways plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest COMPASS Pathways plc(CMPS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction